Table 1 Patient characteristics
Characteristic | Training cohort (n = 753) | Validation cohort (n = 750) | P-value* |
|---|---|---|---|
Sex | |||
Female | 359 (47.7) | 370 (49.3) | 0.520 |
Male | 394 (52.3) | 380 (50.7) | |
Age | |||
<3 years | 175 (23.2) | 174 (23.2) | 0.985 |
3–5 years | 60 (8.0) | 63 (8.4) | 0.760 |
5–10 years | 134 (17.8) | 145 (19.3) | 0.443 |
10–18 years | 323 (42.9) | 318 (42.4) | 0.846 |
>18 years | 61 (8.1) | 50 (6.7) | 0.288 |
WBC Count | |||
<100,000/µL | 594 (79.0) | 586 (78.1) | 0.686 |
≥100,000/µL | 158 (21.0) | 164 (21.9) | |
Unknown | 1 | 0 | |
Cytomolecular risk group | |||
Low | 291 (38.6) | 289 (38.5) | 0.964 |
Standard | 212 (28.2) | 197 (26.3) | 0.411 |
High | 250 (33.2) | 264 (35.2) | 0.414 |
MRD at end of induction I | |||
No | 462 (68.8) | 468 (69.0) | 0.796 |
Yes | 210 (31.3) | 210 (31.0) | |
Unknown | 81 | 72 | |
SCT in CR1 | |||
No | 650 (86.3) | 659 (87.9) | 0.372 |
Yes | 103 (13.7) | 91 (12.1) | |
CEBPA mutation | |||
No | 713 (94.7) | 707 (94.3) | 0.721 |
Yes | 40 (5.3) | 43 (5.7) | |
FLT3-ITD mutation | |||
No | 609 (80.9) | 602 (80.3) | 0.765 |
<0.1 | 26 (3.5) | 28 (3.7) | 0.770 |
≥0.1 | 118 (15.7) | 120 (16.0) | 0.861 |
Fusion category | |||
RUNX1-RUNX1T1 | 101 (13.4) | 101 (13.5) | 0.976 |
CBFB-MYH11 | 82 (10.9) | 82 (10.9) | 0.978 |
KMT2A | 158 (21.0) | 157 (20.9) | 0.981 |
NUP98 | 60 (8.0) | 59 (7.9) | 0.942 |
CBFA2T3-GLIS2 | 14 (1.9) | 13 (1.7) | 0.854 |
Other or no fusion | 338 (44.9) | 338 (45.1) | 0.944 |
